SCHEMBL2834097

SCHEMBL2834097

CC(C)Oc1ccc(C(=O)C(NC(=O)OC(C)(C)C)c2ccc(Cl)cc2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR3 Q99500 2/20 0.47
KMT2A Q03164 4/20 0.44
TRPA1 O75762 2/20 0.43
CTSS P25774 1/20 0.42
CTSK P43235 1/20 0.42
PPARG P37231 2/20 0.42
PPARA Q07869 2/20 0.42
MAPT P10636 3/20 0.41
MEN1 O00255 2/20 0.41
ALDH1A1 P00352 1/20 0.41
HTT P42858 1/20 0.41
LMNA P02545 2/20 0.41
TSHR P16473 2/20 0.41
PARP10 Q53GL7 1/20 0.40
CNR1 P21554 4/20 0.39
CNR2 P34972 2/20 0.39
NPSR1 Q6W5P4 2/20 0.39
USP2 O75604 1/20 0.39
ABCB11 O95342 1/20 0.39
CYP1A2 P05177 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15974098 0.90 S1PR3 (0.48) S1PR3TRPA1CTSSCTSKPPARG
SCHEMBL15974097 0.90 S1PR3 (0.48) S1PR3TRPA1CTSSCTSKPPARG
SCHEMBL17391319 0.90 S1PR3 (0.48) S1PR3TRPA1CTSSCTSKPPARG
SCHEMBL2836204 0.89 S1PR3 (0.48) S1PR3TRPA1CTSSCTSKPPARG
SCHEMBL2837437 0.87 S1PR3 (0.46) S1PR3TRPA1CTSSCTSKPPARG
SCHEMBL2836778 0.86 CHRNA1 (0.42) S1PR3KMT2ATRPA1CTSSCTSK
SCHEMBL2834711 0.85 S1PR3 (0.45) S1PR3TRPA1CTSSCTSKPPARG
SCHEMBL24645190 0.84 S1PR3 (0.53) S1PR3KMT2ATRPA1CTSSCTSK
SCHEMBL2841519 0.83 S1PR3 (0.47) S1PR3TRPA1CTSSCTSKPPARG
SCHEMBL2833809 0.82 S1PR3 (0.50) S1PR3CTSSCTSKPPARGPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8367838-B2 Amines or amino alcohols as GLYT1 inhibitors HOFFMANN-LA ROCHE INC. (US) 2013-02-05 US disclosed
US-20120232033-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS KOLCZEWSKI SABINE (DE) 2012-09-13 US disclosed
EP-2398558-A1 AMINE OR AMINO ALCOHOLS AS GLYT1 INHIBITORS F. Hoffmann-La Roche AG (CH) 2011-12-28 EP disclosed
WO-2010094659-A1 AMINE OR AMINO ALCOHOLS AS GLYT1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2010-08-26 WO disclosed
US-20100210592-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS HOFFMANN-LA ROCHE, INC. 2010-08-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120232033-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS GFPT1, CEPT1, SLC18A2 S1PR3 2311/4885KMT2A 397/4885TRPA1 3113/4885
US-20100210592-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS GFPT1, CEPT1, SLC18A2 S1PR3 2311/4885KMT2A 397/4885TRPA1 3113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.